Civica announces McCoy as new president; VanTrieste to remain on board
Civica Inc., a Lehi-based nonprofit generic drug company, has announced that Ned McCoy, currently Civica’s chief operating officer, has succeeded Martin Van-Trieste as Civica’s president and CEO. The change was effective June 1. VanTrieste will remain an advisor to the company and continue serving on Civica’s board of directors. As part of this transition, McCoy also joined the Civica Board of Directors on June 1.
“Martin’s decision to come out of retirement four years ago to help us shape and launch Civica was critical to bringing together diverse stakeholders to create a more reliable and affordable approach to generic medicines,” said Dan Liljenquist of Utah’s Intermountain Healthcare, chairman of the board of Civica. “From leading the development of Civica’s future essential medicines manufacturing facility to executing numerous pivotal partnership agreements and, most recently, pioneering Civica’s initiative to manufacture and distribute affordable insulin, Martin’s impact will be felt for decades to come. We’re thrilled Martin will continue serving on our board of directors and will help guide the Civica team to build on the many successes during his tenure.”
Civica was created by hospital systems and philanthropies — including Intermountain Healthcare — in 2018 to reduce and prevent chronic drug shortages in hospitals and the unpredictable price spikes that often accompany them. Its mission is to make quality generic medicines accessible and affordable to everyone, the company said when it was founded. To date, Civica has announced its intention to manufacture nearly 60 generic medications. Most recently, Civica and its outpatient arm, CivicaScript, announced plans to develop, manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including insulin beginning in 2024.
“It has been an honor to lead Civica and witness firsthand how our organization has improved so many lives — providing enough essential medicine to help treat over 30 million patients to date,” said VanTrieste. “Our team’s dedication and passion for building an innovative, transformative generic medication model constantly inspires me. I look forward to continuing to be a part of Civica as a member of the board and supporting Ned as he takes on this exciting role.”
McCoy has led efforts to secure manufacturing partnerships for Civica. He has also been deeply involved with Civica’s commercial team and stakeholders. Most recently, McCoy orchestrated the partnership with Civica’s insulin development partner, GeneSys Biologics, with the plan to bring Civica biosimilar insulins to market. Prior to Civica, McCoy served at Abbott for 32 years, where he led teams in hospital products, pharmaceutical products, nutrition and corporate mergers and acquisitions. McCoy received his bachelor’s and master of science degrees in chemical engineering from North Carolina State University.
“On behalf of the board, we’re thrilled that Ned will take on this new role, leveraging his strong track record of leading companies to significant growth and executing complementary partnerships,” said Liljenquist. “I and the entire board have complete confidence that he will further build on Civica’s important work to serve even more patients and transform the medication landscape.”
“I am honored to serve as the next CEO of Civica and continue our pivotal work of delivering quality generic medications that are available and affordable to everyone,” said McCoy. “Through much of my time at Civica, I have had the privilege of leading Civica’s operations, including helping to secure successful, long-term manufacturing partnerships and execute the building of our own manufacturing facility. I look forward continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines.”